Sharon Wilks
Texas Oncology(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA(2020)1,444 cited
- → Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial(2014)490 cited
- → Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3(2016)165 cited
- → Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study(2021)135 cited
- → PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer(2016)134 cited
- → nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial(2018)132 cited
- → Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial(2019)113 cited
- → Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer(2021)107 cited
- → Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway(2015)93 cited
- → Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer(2014)69 cited